Metformin Compared With Myo-inositol for Polycystic Ovary Syndrome
Compares metformin and myo-inositol as treatments for women with polycystic ovary syndrome.
Plain-language title generated from the registry record
Registry title: Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study
Key facts
- Where
- Chak One Hundred Seventy-five Nine Left, PakistanSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 16 to 45 with polycystic ovary syndrome (PCOS). It compares Metformin with Myo-inositol.
- Age
- 16 Years to 45 Years
- Sex
- Women only
- Disease stage
- Diagnosed with PCOS: irregular cycles for more than 3 months, with hirsutism, acne, and polycystic ovaries seen on ultrasound.
- Earlier treatment
- Cannot have already taken or be taking PCOS treatment, or the trial drugs.
Main reasons for not taking part
- Already taking or having taken PCOS treatment
- Already enrolled in another trial program
- Chronic diabetes (BSR>200 mg/dl) or hypertension (BP≥140/90mmHg)
- Pregnancy (gestational sac seen on ultrasound)
- Allergy to any content of the trial drugs
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 45 years old?
Source: NCT07459595, who can take part
Where in Pakistan
- CMH GujranwalaChak One Hundred Seventy-five Nine Left, PakistanContact: Dr Syeda Uzma, MBBS, FCPSNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fatima Tariq
- Trial code
- NCT07459595
- Record updated
- 10 March 2026
- Original description
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.Read full original descriptionShow less
Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study
In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound.
The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Inclusion: Married or unmarried; Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).
Exclusion: Females already taking trial drugs; Females allergic to any content of trial drugs (on history); Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg); Females already taken or taking PCOS treatment (on medical record); Females already enrolled in another trial program; Females with PCOS along with gestational sac (on ultrasound).